AlphAIalphai — Financial news for AI agents
marketscreener.comAUG 191 min read$HSIC

BTIG Adjusts Price Target on Henry Schein to $110 From $100, Maintains Buy Rating

BTIG raised its price target on Henry Schein to $110 from $100 while maintaining a Buy rating. The stock is currently trading at $89.57, up 0.38% on the day but down 1.28% over the past year. Barclays also recently adjusted its target to $100 from $86.

Original reporting
marketscreener.com
Published Aug 19, 2026, 9:53 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 4:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$HSIC
Bullish
medium confidence
Mentioned
$HSIC
Relevance
7/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

$HSICBullishMed
01

Why it matters

The upgrade signals a modest upside but lacks fresh fundamental catalysts.

02

Market read

Analyst target changes can influence short‑term price action, especially in pre‑market trading.

03

What to watch

No accompanying earnings beat or new contract disclosed.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

BTIG's price‑target adjustment is part of routine analyst coverage updates.

Company-level read

Ticker impact

$HSICBullishMedium confidence
Context

BTIG raised its price target for Henry Schein to $110 from $100, indicating a more bullish outlook.

Expected impact

Potential modest upside of 3‑5% over the next week.

Evidence & confidence

Target raise reflects improved valuation expectations; however, no new fundamental data accompanies the change.

Market effects

Sector

May lift sentiment for the medical‑distribution sector.

Regional

Limited to U.S. healthcare equities.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Target raise could be premature if earnings guidance remains unchanged.

Key entities

  • Company
    Henry Schein

    U.S. medical‑equipment distributor (ticker HSIC).

  • Analyst
    BTIG

    Equity research firm issuing the target change.

Read at source← All news

Related articles

AUG 19
$HSICMed

Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?

Henry Schein, Inc. (HSIC) reported broad-based growth in Q2, with sales increases across distribution, specialty products, and technology. Management raised its 2026 sales and earnings guidance. HSIC trades at a discount to market benchmarks but faces risks from leverage and execution challenges. The company aims for $200M in operating income improvement by 2026, with savings initiatives underway.

tradingview.com3 min
AUG 11
$HSICMedAI 8/10

Henry Schein (HSIC) Q2 2026 Earnings Call Transcript

Henry Schein (HSIC) reported Q2 2026 net sales of $3.5 billion, up 6.7%, and non-GAAP diluted EPS of $1.27. GAAP diluted EPS was $0.82. The company raised 2026 guidance, including non-GAAP EPS to $5.29 to $5.39 and sales growth to 4.5% to 5.5%, and approved $200 million in share repurchases.

fool.com6 min
AUG 7
$HSICMed

Henry Schein Recasts Its Future Around AI, Simpler Leadership and Faster Execution

Henry Schein Inc. outlined a transformation focused on AI, simpler leadership, and faster execution in its first earnings report under CEO Fred Lowery. The company reported Q2 net sales of $3.46B (+6.7%) and net income of $94M (+9.3%), raised its 2026 sales outlook to 4.5% to 5.5%, and announced a leadership reorganization integrating supply chain and distribution. It targets $200M+ operating improvements.

distributionstrategy.com7 min
AUG 6
$HSICMedAI 8/10

Henry Schein, Inc. Q2 2026 Earnings Call Summary

Henry Schein reported Q2 2026 progress including faster internal local-currency sales growth, driven by dental merchandise market-share gains and higher technology platform share. The company raised full-year 2026 sales growth guidance to 4.5% to 5.5% and expects $125 million operating income improvement run rate by end-2026. Restructuring expenses were $29 million.

yahoo.com6 min
AUG 4
$HSICMedAI 8/10

Henry Schein (NASDAQ:HSIC) Surprises With Q2 CY2026 Sales

Henry Schein (NASDAQ:HSIC) reported Q2 CY2026 results with revenue up 6.7% year on year to $3.46 billion, exceeding Wall Street estimates by 2.6%, according to the company. Non-GAAP adjusted EPS was $1.27, up from $1.10, beating consensus by 2.5%. Adjusted operating margin was 5.3%. Analysts expect revenue growth of 2.9% over the next 12 months.

financialcontent.com3 min
AUG 4
$HSICHigh

HENRY SCHEIN INC (HSIC): Results of Operations and Financial Condition

HENRY SCHEIN INC (HSIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. -1- more FOR IMMEDIATE RELEASE HENRY SCHEIN REPORTS STRONG SECOND QUARTER 2026 FINANCIAL RESULTS AND RAISES FY2026 GUIDANCE ● Q2 2026 GAAP diluted EPS of $0.82 compared to $0.70 GAAP diluted EPS in Q2 2025 ● Q2 2026 non-GAAP diluted EPS of $1.27 compared to $1.10 non-GAAP diluted

SEC EDGAR 8-K6 min